Peter Altman, serving as President and Chief Executive Officer of BioCardia, Inc. (NASDAQ:BCDA), has expanded his personal stake in the biotechnology firm through a series of targeted equity acquisitions. The executive purchased a cumulative total of 7,500 shares of BioCardia common stock, executing the transactions across three consecutive trading days in early July 2026. The aggregate value of these purchases stood at $7,175.
On July 8, 2026, Altman initiated the buying activity by acquiring 5,500 shares. This specific block was not executed as a single block trade but was instead fragmented across multiple transactions. The individual share prices for this portion of the acquisition varied between $0.92 and $1.05, resulting in a weighted average purchase price of $0.97 per share. Subsequent purchases followed on the next two trading days. On July 9, 2026, he acquired an additional 1,000 shares at a price of $0.90 per share. The final tranche of this recent accumulation occurred on July 10, 2026, when 1,000 more shares were obtained at $0.94 per share.
All reported transactions represent direct ownership stakes, meaning the shares were purchased outright rather than through options or other derivative instruments. Following the completion of these purchases, Mr. Altman's direct ownership position in BioCardia common stock stands at 369,485 shares. The insider buying activity takes place against a backdrop of recent stock price volatility. According to data from InvestingPro, the company's shares have declined nearly 24% over the past week. At the time of the reporting, the stock was trading at $0.92, which falls within the price range of the executive's recent acquisitions. Market analysis tools have flagged BioCardia as potentially undervalued at current levels, placing it on specific screening lists designed to identify stocks trading below intrinsic value estimates.
Beyond the executive transaction, BioCardia has advanced its regulatory and capital strategy. The company announced intentions to submit its CardiAMP Cell Therapy for regulatory approval in Japan by the conclusion of 2026. This submission follows constructive engagement with Japan’s Pharmaceutical and Medical Device Agency. The regulatory body has aligned with BioCardia on the necessary procedural steps required for approval, specifically targeting a patient subgroup of 20,000 individuals diagnosed with ischemic heart failure. Concurrently, the company successfully closed a capital raise, securing approximately $4.5 million. This funding was generated through a direct share sale involving the issuance of 3,509,604 shares, executed without the attachment of any warrants.
Regulatory progress in the United States also provides a positive development for the firm. The U.S. Food and Drug Administration (FDA) has confirmed that its ongoing CardiAMP Heart Failure II Trial may provide sufficient data to support a Premarket Approval application for market clearance. This feedback was issued by the FDA Center for Biologics Evaluation and Research. The CardiAMP Cell Therapy System is designed to treat ischemic heart failure characterized by reduced ejection fraction. The agency noted that approval for such large clinical indications typically requires two well-designed trials. These regulatory milestones and capital formation efforts constitute the core of BioCardia's ongoing strategy to advance its therapeutic solutions within the broader healthcare market.